Your browser is no longer supported. Please, upgrade your browser.
Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.16 Insider Own29.37% Shs Outstand121.85M Perf Week-13.48%
Market Cap187.65M Forward P/E- EPS next Y-0.77 Insider Trans0.00% Shs Float81.63M Perf Month-33.62%
Income-261.90M PEG- EPS next Q-0.43 Inst Own21.90% Short Float15.47% Perf Quarter-38.65%
Sales23.70M P/S7.92 EPS this Y7.80% Inst Trans0.24% Short Ratio10.41 Perf Half Y-62.16%
Book/sh0.68 P/B2.26 EPS next Y57.10% ROA-43.50% Target Price25.50 Perf Year-55.36%
Cash/sh0.51 P/C3.04 EPS next 5Y37.00% ROE-162.10% 52W Range1.39 - 6.50 Perf YTD-35.83%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-34.40% 52W High-75.08% Beta2.53
Dividend %- Quick Ratio0.80 Sales past 5Y115.10% Gross Margin57.30% 52W Low16.55% ATR0.23
Employees382 Current Ratio0.80 Sales Q/Q66.70% Oper. Margin- RSI (14)37.28 Volatility13.58% 12.03%
OptionableYes Debt/Eq3.06 EPS Q/Q36.90% Profit Margin- Rel Volume1.15 Prev Close1.54
ShortableYes LT Debt/Eq2.68 EarningsNov 08 AMC Payout- Avg Volume1.21M Price1.62
Recom2.00 SMA20-20.09% SMA50-24.07% SMA200-42.05% Volume652,063 Change5.19%
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Oct-09-19 10:35AM  Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering GlobeNewswire
Oct-07-19 02:35PM  Sorrento Therapeutics Announces $25 Million Registered Direct Offering GlobeNewswire -25.52%
Sep-30-19 07:00AM  Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak GlobeNewswire
Sep-23-19 07:00AM  Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering GlobeNewswire
Aug-14-19 08:33AM  Those Who Purchased Sorrento Therapeutics (NASDAQ:SRNE) Shares Three Years Ago Have A 67% Loss To Show For It Simply Wall St.
Aug-01-19 10:33AM  Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.32%
Jul-29-19 10:12AM  Moving Average Crossover Alert: Sorrento Therapeutics Zacks
Jul-02-19 12:40PM  Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
Jul-01-19 08:46AM  Implied Volatility Surging for Sorrento (SRNE) Stock Options Zacks
Jun-28-19 04:40PM  Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today Motley Fool -21.24%
12:18PM  Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering InvestorPlace
08:37AM  Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
06:00AM  Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Jun-19-19 11:51AM  Sorrento Therapeutics Shares Move On RTX Trial Update Benzinga
07:00AM  Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial GlobeNewswire
07:00AM  Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for Off-The-Shelf Cell Therapy GlobeNewswire
Jun-14-19 07:00AM  Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY) GlobeNewswire
Jun-12-19 07:00AM  Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company GlobeNewswire
Jun-10-19 07:00AM  Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain GlobeNewswire
Jun-05-19 07:00AM  Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration GlobeNewswire
Jun-04-19 07:00AM  Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships GlobeNewswire +5.57%
May-29-19 01:03PM  Why Sorrento Therapeutics Is Getting Crushed Today Motley Fool -10.33%
May-21-19 06:25PM  Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca). GlobeNewswire
May-20-19 08:50AM  Options Traders Expect Huge Moves in Sorrento (SRNE) Stock Zacks
May-03-19 10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
Apr-18-19 08:30AM  Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc. ACCESSWIRE
Apr-16-19 09:00AM  Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations GlobeNewswire
Apr-15-19 04:00AM  Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study GlobeNewswire
Apr-10-19 12:42PM  Why Sorrento Therapeutics Is Jumping Today Motley Fool
09:00AM  Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinsons Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration GlobeNewswire
Apr-09-19 12:59PM  Here's Why Sorrento Therapeutics Soared 134% in March Motley Fool
Apr-04-19 03:54PM  Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme American City Business Journals
08:50AM  Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock? Zacks
Apr-03-19 01:50AM  Patrick Soon-Shiong accused of cancer drug catch and kill Financial Times +15.26%
Mar-26-19 08:30AM  Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program GlobeNewswire
Mar-22-19 01:06PM  Sorrento Therapeutics News: Why SRNE Stock Is On The Move InvestorPlace +13.58%
07:00AM  Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management GlobeNewswire
Mar-11-19 07:00AM  Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001 GlobeNewswire
Feb-25-19 07:00AM  Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences GlobeNewswire
Feb-12-19 07:00AM  Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program GlobeNewswire
Feb-08-19 09:06AM  What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)? Simply Wall St.
Jan-31-19 08:20AM  New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -5.07%
Jan-22-19 09:30AM  Health Stocks Benefitting the Most from Rally ACCESSWIRE -6.52%
07:00AM  Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019 GlobeNewswire
Jan-14-19 07:00AM  Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1) GlobeNewswire -6.48%
07:00AM  Scilex Announces Addition of ZTlido® to Express Scripts National Formularies GlobeNewswire
Jan-04-19 07:00AM  Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference GlobeNewswire
Nov-08-18 07:00AM  Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million GlobeNewswire -5.66%
Nov-06-18 08:01AM  Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases GlobeNewswire
Nov-01-18 07:00AM  Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma GlobeNewswire +12.85%
Oct-25-18 08:10AM  Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +7.89%
Oct-11-18 05:04PM  Here's Why Sorrento Therapeutics Fell 20.7% in September Motley Fool
Oct-05-18 02:16PM  10 Growth Stocks to Buy With Monster Potential Kiplinger
Oct-01-18 08:00AM  Scilex Announces the Availability of ZTlido GlobeNewswire -6.14%
Sep-27-18 06:09PM  Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018 GlobeNewswire
Sep-19-18 08:00AM  Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018 GlobeNewswire
Sep-10-18 04:00AM  Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication GlobeNewswire +11.11%
Sep-07-18 12:24PM  Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation PR Newswire
Sep-04-18 08:30AM  Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-02-18 01:19PM  Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY) GlobeNewswire
Aug-13-18 09:42AM  Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data Benzinga
04:00AM  1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations GlobeNewswire
Jul-23-18 08:10AM  Todays Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics ACCESSWIRE
07:05AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-05-18 05:32PM  Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today Motley Fool -7.75%
04:11PM  Why Sorrento Therapeutics, Inc. Stock Sank Today Motley Fool
Jul-03-18 09:30AM  Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics GlobeNewswire
Jun-26-18 07:15AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE +11.81%
Jun-14-18 04:42PM  Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders GlobeNewswire
10:31AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
10:18AM  Hong Kong market could open cash flood gates for U.S. biotechs Reuters
May-25-18 07:10AM  Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-24-18 07:47PM  An Intrinsic Calculation For Sorrento Therapeutics Inc (NASDAQ:SRNE) Shows Its 26% Undervalued Simply Wall St. +5.30%
May-11-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeutics, TD Ameritrade Holding, Meritor, and DXC Technology Fundamental Analysis, Key Performance Indications GlobeNewswire
May-08-18 08:30AM  Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina ACCESSWIRE
Apr-24-18 01:43PM  Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc. PR Newswire
Apr-23-18 08:00AM  Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on Unite to Cure GlobeNewswire
Apr-16-18 07:01PM  Cramer's lightning round: Take a long-term view on Spotif... CNBC Videos +11.11%
06:50PM  Cramer's lightning round: Take a long-term view on Spotify CNBC
Apr-05-18 02:53PM  Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916) GlobeNewswire
Apr-04-18 05:46PM  Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18 GlobeNewswire +7.84%
Mar-28-18 07:28PM  Sorrento Therapeutics Chairman/CEO update to stockholders GlobeNewswire -26.98%
04:18PM  Why Sorrento Therapeutics Inc. Is Getting Beaten Down Today Motley Fool
Mar-27-18 08:00AM  Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing GlobeNewswire -10.00%
Mar-20-18 11:03PM  Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18 GlobeNewswire +6.62%
Mar-19-18 08:00AM  Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 GlobeNewswire
Mar-14-18 10:08PM  Sorrento Therapeutics to Present at the 28th Annual Oppenheimer Conference (NY) on 03/20/18 GlobeNewswire
05:48PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE) Business Wire
Mar-08-18 06:16PM  Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18 GlobeNewswire
Mar-05-18 08:00AM  Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage IV Pancreas Cancer in a Phase 1b HITM-SURE Trial (NCT02850536) GlobeNewswire
Mar-01-18 06:53PM  Why an FDA Approval Caused Sorrento Therapeutics' Pain Motley Fool -24.12%
08:20AM  Todays Research Reports on Stocks to Watch: Sorrento Therapeutics and Celgene Corporation ACCESSWIRE
07:19AM  Heres Why Sorrento Is Running Today Market Exclusive
Feb-28-18 03:47PM  FDA approves Sorrento's non-opioid painkiller patch, shares jump Reuters +17.75%
02:16PM  FDA approves Sorrento's painkiller patch Reuters
02:12PM  Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain GlobeNewswire
Feb-27-18 01:49PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE PR Newswire
01:41PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sorrento Therapeutics, Inc. (SRNE) PR Newswire
Feb-17-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-15-18 01:19PM  Why Sorrento Therapeutics Jumped Higher Today Motley Fool +9.70%
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The company has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.